Latin America Lipid Optimization After Acute Event in Patients With AthErosclerotic CardiovasculaR DiseaSe and High LDL-C
Latest Information Update: 21 Aug 2025
At a glance
- Drugs Inclisiran (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms LATAM LOWERS LDL-C
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 19 Jun 2025 Planned number of patients changed from 520 to 500.
- 14 Mar 2025 Planned primary completion date changed from 29 Nov 2026 to 27 Nov 2026.
- 14 Mar 2025 Status changed from not yet recruiting to recruiting.